|View printer-friendly version|
|January 02, 2001 11:21 a.m.|
|Teva Reaffirms Confidence in Sales of Sustained Release Generic Products|
Jerusalem, Israel, January 2, 2001 - Dan Suesskind, Chief Financial Officer of Teva Pharmaceuticals Industries Ltd. (NASDAQ:TEVA), responding to statements attributed to Teva in a January 2, 2001 analysts conference call by Biovail Corporation (NASDAQ:BVF), stated: 'While it is generally not our policy to comment on the public announcements of other parties, I would like to correct a negative implication in today's Biovail conference call regarding Teva's sales of Biovail products and Teva's own corporate performance. Teva's internal forecasts regarding its sales of the sustained release generic products produced by Biovail remain strong and unchanged. We do not foresee a shortfall in our sales of these products.'